{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:39:56Z","timestamp":1790170796132,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:00:00Z","timestamp":1513814400000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003006","name":"ETH Z\u00fcrich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["310030B_163479\/1"],"award-info":[{"award-number":["310030B_163479\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["SINERGIA CRSII2_160699\/1"],"award-info":[{"award-number":["SINERGIA CRSII2_160699\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"ERC","doi-asserted-by":"publisher","award":["17072.1"],"award-info":[{"award-number":["17072.1"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bovena Foundation"},{"name":"Maiores Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jconrel.2016.11.023","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T18:02:02Z","timestamp":1480010522000},"page":"39-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma"],"prefix":"10.1016","volume":"246","author":[{"given":"Samuele","family":"Cazzamalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4437-8307","authenticated-orcid":false,"given":"Alberto","family":"Dal Corso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2016.11.023_bb0005","first-page":"1195","article-title":"Elucidation of the mechanism enabling tumor selective prodrug monotherapy","volume":"58","author":"Bosslet","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0010","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00259-008-0744-y","article-title":"Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer","volume":"35","author":"Cao","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2016.11.023_bb0015","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1007\/s00259-010-1489-y","article-title":"Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients","volume":"37","author":"van der Veldt","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2016.11.023_bb0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cbpa.2010.06.170","article-title":"Antibody-drug conjugates: targeted drug delivery for cancer","volume":"14","author":"Alley","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1039\/c3np20113a","article-title":"The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics","volume":"30","author":"Gerber","year":"2013","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0030","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2217\/fon.12.189","article-title":"Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia","volume":"9","author":"Chu","year":"2013","journal-title":"Future Oncol."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0040","first-page":"84","article-title":"The pharmacokinetics and pharmacodynamics of monoclonal antibodies\u2013mechanistic modeling applied to drug development","volume":"10","author":"Mould","year":"2007","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0045","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/1535-7163.MCT-11-0742-T","article-title":"Effects of anti-VEGF on pharmacokinetics, biodistribution, and ttumor penetration of trastuzumab in a preclinical breast cancer model","volume":"11","author":"Pastuskovas","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0050","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.jconrel.2016.11.023_bb0055","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00280-007-0560-2","article-title":"Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples","volume":"61","author":"Boghaert","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0060","doi-asserted-by":"crossref","DOI":"10.1021\/acs.analchem.6b00976","article-title":"Where did the linker-payload go? A quantitative investigation on the destination of the releasedlinker-payload from an antibody-drug conjugate with a maleimide linker in plasma","volume":"88","author":"Wei","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0065","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.1021\/acs.jmedchem.5b00457","article-title":"Antibody-drug conjugates and small molecule-drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents","volume":"58","author":"Casi","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0070","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/0008-5472.CAN-06-2531","article-title":"Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent","volume":"67","author":"Dennis","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0075","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1021\/mp900158d","article-title":"Real time, noninvasive imaging and quantitation of the accumulation of ligand-targeted drugs into receptor-expressing solid tumors","volume":"6","author":"Vlashi","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0080","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1021\/mp900069d","article-title":"Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand","volume":"6","author":"Kularatne","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0085","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1021\/jm100509v","article-title":"Folate-targeted therapies for cancer","volume":"53","author":"Xia","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0090","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1021\/bc2005522","article-title":"Engineering folate-drug conjugates to target cancer: from chemistry to clinic","volume":"23","author":"Vlahov","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0095","doi-asserted-by":"crossref","first-page":"7767","DOI":"10.1021\/jm100729b","article-title":"Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs","volume":"53","author":"Kularatne","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0100","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1021\/mp0700514","article-title":"Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones","volume":"4","author":"Engel","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd4519","article-title":"Principles in the design of ligand-targeted cancer therapeutics and imaging agents","volume":"14","author":"Srinivasarao","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0110","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.tips.2006.09.002","article-title":"Targeting tumor-associated carbonic anhydrase IX in cancer therapy","volume":"27","author":"Thiry","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0115","first-page":"245","article-title":"Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy","volume":"2","author":"Pastorekova","year":"2004","journal-title":"Cancer Ther."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5306\/wjco.v3.i7.98","article-title":"Inhibition of carbonic anhydrase IX as a novel anticancer mechanism","volume":"7","author":"Supuran","year":"2012","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0125","first-page":"7075","article-title":"Hypoxia-inducible expression of tumor-associated carbonic anhydrases","volume":"60","author":"Wykoff","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0130","first-page":"495","article-title":"Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models","volume":"46","author":"van Schaijk","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0135","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1021\/acs.bioconjchem.6b00271","article-title":"Evaluation of nonpeptidic ligand conjugates for SPECT imaging of hypoxic and carbonic anhydrase IX-expressing cancers","volume":"27","author":"Lv","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0140","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1158\/0008-5472.CAN-15-2962","article-title":"Darwinian dynamics of intratumoral heterogeneity: not solely random mutations but also variable environmental selection forces","volume":"76","author":"Lloyd","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0145","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1158\/1535-7163.MCT-11-0523","article-title":"Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9","volume":"11","author":"Petrul","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0150","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1002\/anie.201310709","article-title":"A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors","volume":"53","author":"Krall","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0155","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-16-0283","article-title":"Acetazolamide serves as selective delivery vehicle for dipeptide-linked drugs to renal cell carcinoma","author":"Cazzamalli","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0160","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1039\/C4SC00685B","article-title":"A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in mice","volume":"5","author":"Krall","year":"2014","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0165","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2967\/jnumed.115.170514","article-title":"A 99mTc-labeled ligand of carbonic anhydrase IX selectively targets renal cell carcinoma in vivo","volume":"57","author":"Krall","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0170","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1158\/0008-5472.CAN-13-2990","article-title":"Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids","volume":"74","author":"Perrino","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0175","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-15-0480","article-title":"Antibody format and drug release rate determine the therapeutic activity of noninternalizing antibody-drug conjugates","volume":"14","author":"G\u00e9bleux","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0180","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2014.06.012","article-title":"Disulfide-containing parenteral delivery systems and their redox-biological fate","volume":"195","author":"Br\u00fclisauer","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.11.023_bb0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-62703-541-5_2","article-title":"Antibody-drug conjugate target selection: critical factors","volume":"1045","author":"Bander","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0190","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1007\/s11095-015-1729-8","article-title":"Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates","volume":"32","author":"Xu","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0195","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1016\/j.bmc.2015.09.050","article-title":"Ultrasmall dual-modality silica nanoparticle drug conjugates: design, synthesis, and characterization","volume":"15","author":"Yoo","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0200","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0205","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/bc025536j","article-title":"Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity","volume":"13","author":"Dubowchik","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0210","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nchem.2158","article-title":"Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation","volume":"7","author":"Wichert","year":"2015","journal-title":"Nat. Chem."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0215","first-page":"310","article-title":"Sequence of treatment in locally advanced and metastatic renal cell carcinoma","volume":"4","author":"Fischer","year":"2015","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0220","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.bmcl.2012.02.068","article-title":"Radioiodinated sunitinib as a potential radiotracer for imaging angiogenesis-radiosynthesis and first radiopharmacological evaluation of 5-[125I]Iodo-sunitinib","volume":"22","author":"Kuchar","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0225","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.nucmedbio.2013.02.002","article-title":"[11C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer","volume":"40","author":"Poot","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0230","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ctrv.2014.12.012","article-title":"Drug radiotherapy combinations: review of previous failures and reasons for future optimism","volume":"41","author":"Higgins","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0240","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/S0960-894X(98)00609-X","article-title":"Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin","author":"Dubowchik","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0245","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0250","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0255","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/1535-7163.MCT-13-1067","article-title":"Dual targeting of integrin \u03b1v\u03b23 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery","volume":"13","author":"Crisp","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0260","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1021\/bc100097r","article-title":"Conjugates of a novel 7-substituted camptothecin with RGD-peptides as \u03b1v\u03b23 integrin ligands: an approach to tumor-targeted therapy","volume":"21","author":"Dal Pozzo","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0265","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1021\/jm300493m","article-title":"Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix","volume":"55","author":"Hochd\u00f6rffer","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0270","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.1002\/chem.201500158","article-title":"Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers","volume":"21","author":"Dal Corso","year":"2015","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0275","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/2326-6066.CIR-13-0007","article-title":"Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study","volume":"1","author":"Poli","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2016.11.023_bb0280","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2967\/jnumed.112.111310","article-title":"Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients","volume":"54","author":"Heuveling","year":"2013","journal-title":"J. Nucl. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916307350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916307350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:31:54Z","timestamp":1759159914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916307350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":56,"alternative-id":["S0168365916307350"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.11.023","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}